GlassScriptPhysician profile
Francisco X Valls
NPI 1629044193
$2,549.75
in general payments reported to CMS, 2019-2025
26 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $210 · 2021: $231 · 2023: $334 · 2024: $942 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.25 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $304.24 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $251.22 | 2023-2025 | Vraylar |
| Pfizer INC. | $188.55 | 2019-2025 | |
| Shield Therapeutics INC | $178.15 | 2024-2025 | |
| Abbott Laboratories | $177.06 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $157.05 | 2019-2025 | Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $125.82 | 2019-2023 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $117.17 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $78.38 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $76.99 | 2020-2025 | Evenity, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $62.02 | 2019-2025 | Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $56.68 | 2019 | |
| Xeris Pharmaceuticals, INC. | $52.89 | 2021-2024 | Keveyis, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.80 | 2019-2025 | Jardiance, Tradjenta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.85 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $37.37 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $34.91 | 2024 | Voquezna |
| Exact Sciences Corporation | $33.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $29.56 | 2020-2024 | Veozah |
| Genentech USA, INC. | $28.30 | 2019-2020 | |
| Boston Scientific Corporation | $23.87 | 2024 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $21.23 | 2021 | |
| Optinose US, INC. | $18.12 | 2024 | |
| Mylan Specialty L.P. | $16.59 | 2023 | Yupelri |
| Biogen, INC. | $14.82 | 2025 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Valls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.